跳至主要内容
临床试验/CTRI/2021/12/038637
CTRI/2021/12/038637进行中(未招募)4 期

A post approval for restricted use under emergency situation study to evaluate the Safety and Efficacy of DESREM LQTM in patients with Moderate to Severe Covid-19 in Indian population.

Mylan Laboratories Limited13 个研究点 分布在 1 个国家目标入组 202 人开始时间: 2022年1月29日最近更新:
适应症

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
202
试验地点
13
主要终点
Incidence of treatment emergent AEs and SAEs

研究概览

简要总结

This will be a post approval for restricted use under emergency situation study, interventional, prospective, multi-center, open-label study to evaluate the safety and efficacy of DESREM LQTM in Indian patients with moderate to severe Covid-19 disease.

Primary objective is to assess the Safety and Tolerability of DESREM LQ TMin patients with moderate to severe Covid 19, by determining incidence of Adverse events during

DESREM LQ TM  treatment and upto Day 28 from enrollment.

Secondary objective is to determine mortality at day 28

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • •Confirmed Covid-19 infection
  • •Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures
  • •Subject (or legally authorized representative) understands and agrees to comply with planned study procedures
  • •Male or non-pregnant female adult ≥ 18 years of age at time of enrollment
  • •Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following: • PCR positive in sample collected < 72 hours prior to enrollment; OR • PCR positive in sample collected ≥ 72 hours prior to enrollment, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection
  • •Illness of any duration, and at least one of the following: Meeting the updated MoHFW (Ministry of Health and Family welfare, Government of India) Clinical Guidance For Management of Adult COVID-19 Patients (Dated 22 Apr 2021): Clinical severity of moderate to severe.
  • •Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 28
  • •Agrees to not participate in another clinical trial for the treatment of COVID-19 or any other indications through Day 28.

排除标准

  • •Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 3 times the upper limit of normal
  • •Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration)
  • •Pregnancy or breast feeding
  • •Subjects with <40 kg body weight
  • •Subjects who are on mechanical ventilation or ECMO (Extracorporeal membrane oxygenation)
  • •Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours
  • •Hypersensitivity to any ingredient of DESREM LQTM
  • •Any other condition as per the physician’s discretion which would make the patient unsuitable for enrollment in the study
  • •Patients who are on or would require any other investigational therapies/products for the treatment of Covid-19 disease.

结局指标

主要结局

Incidence of treatment emergent AEs and SAEs

时间窗: Day 1 to Day 28

次要结局

  • Mortality(Percentage of patients with atleast Two point improvement from baseline in clinical status on the 8 Point ordinal scale)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (13)

Loading locations...

相似试验